See the DrugPatentWatch profile for lurbinectedin

According to available information, there is at least one serious reaction linked to the use of lurbinectedin. The U.S. Food and Drug Administration (FDA) has identified neutropenia, a condition characterized by an abnormally low number of neutrophils (a type of white blood cell) in the blood, as a serious reaction to lurbinectedin [1].

Lurbinectedin is a selective inhibitor of oncogenic transcription and a microtubule dynamics inhibitor, and it is used for the treatment of metastatic small cell lung cancer [1]. The FDA granted accelerated approval for lurbinectedin in June 2020 [1].

The FDA-approved prescribing information for lurbinectedin includes a boxed warning for severe neutropenia [1]. The boxed warning is the strongest warning that the FDA requires, indicating that medical studies identify the drug as causing serious or life-threatening risks [1].

According to DrugPatentWatch.com, lurbinectedin is a drug that is still under patent protection, and it is marketed under the brand name Zepzelca [2].

In summary, the FDA has identified neutropenia as a serious reaction linked to the use of lurbinectedin. Healthcare providers should monitor patients receiving lurbinectedin for signs of neutropenia and take appropriate measures to manage this serious reaction [1].

Sources:
[1] U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer>.
[2] DrugPatentWatch.com. (n.d.). Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>.